The clinical epidemiology of pneumonia in hemodialysis patients has received little attention. We linked the retrospective Waves 1, 3, and 4 Dialysis Morbidity and Mortality Study data sets (n ¼ 10 635) to Medicare claims to identify hospitalizations with pneumonia. Mean patient age was 60.3 years and duration of end-stage renal disease (ESRD) 3.8 years; 41.1% of patients had diabetes mellitus. Only 31.6% had received influenza vaccination in the 4 months preceding the study start date (January 1, 1994). The cumulative probability of pneumonia hospitalization was 0.09 at 1 year and 0.36 at 5 years. The main associations of hospitalization with pneumonia were age 45-64 years and X65 years (adjusted hazards ratio (AHR) 1.26 and 1.48 vs o45 years), chronic lung disease (AHR 1.62), ESRD duration X10 years (AHR 0.75 vs o5 years), body mass index (AHR 0.66 for 25.0-29.9, 0.58 for X30 vs o18.5 kg/m 2 ), serum albumin (AHR 0.74 for X4.06 vs p3.42), and transplantation as a time-dependent covariate (AHR 0.68). One-and 5-year post-pneumonia survival probabilities were 0.55 and 0.17 (vs 0.76 and 0.29 in the overall study population). Adjusted mortality hazards ratios were 4.08 (95% confidence interval (CI) 3.41-4.89) for the 0-to 6-month interval after pneumonia, 3.04 (95% CI 2.58-3.66) for 6-to 12-months, and 2.31 (95% CI 1.97-2.71) for 12-18 months, and remained approximately twofold thereafter. Hospitalization with pneumonia is common in hemodialysis patients and carries a poor prognosis.
Registry studies typically rank infection second to cardiovascular disease as a cause of death in dialysis populations, and approximately one in every five infectious deaths is attributed to pulmonary causes. 1 It has been estimated that mortality rates from pulmonary infections in dialysis patients are 14-16 times higher than in the general population. 2 Thus, pulmonary infections may contribute to the sizeable morbidity and mortality of dialysis patients. In the US, for example, some estimates suggest that pulmonary infections account for up to 115 hospital admissions per 1000 patientyears at risk in hemodialysis patients. 1 Another study suggested that nosocomial infections, including pneumonia, are approximately two times more common than expected in hospitalized hemodialysis patients. 3 The ability of dialysis patients to combat infection may be impaired by the chronic uremic milieu as well as by age and multiple comorbid conditions. 4 It is surprising, then, that the clinical epidemiology of pneumonia in dialysis patients has received comparatively little research attention. For example, a PubMed search performed on March 6, 2006 , using the terms maintenance dialysis and cardiovascular yielded 494 citations. In contrast, only 14 citations were found when pneumonia was substituted for cardiovascular. To the best of our knowledge, few if any studies have attempted to estimate the incidence, risk factors, and prognosis of pneumonia in dialysis patients.
The objectives of this study were to define the clinical epidemiology of pneumonia in hemodialysis patients. Specifically, we wished to define: (1) cumulative pneumoniafree survival over time, (2) microbiologic attribution of index events, (3) antecedent associations, and (4) association with mortality.
date, absence of Medicare Part A as primary coverage, and date of first end-stage renal disease (ESRD) service day less than 90 days before December 31, 1993. This strategy produced a final sample size of 10 635. Table 1 shows the baseline characteristics of the study population. The mean patient age was 60.3 years and duration of ESRD 3.8 years; 51.1% of patients were male, 49.5% white, 24.3% had ESRD for 5 or more years, and 41.1% had diabetes mellitus as a comorbid condition. Before the study start date of January 1, 1994, 11.3% of patients had been waitlisted for kidney or kidney-pancreas transplants. In the 5 years before the study start, 8.7% of patients received vaccination for pneumonia; 9.1% of those with ESRD duration between 5 and 10 years and 8.5% of those with ESRD duration greater than 10 years received vaccination for pneumonia. In the 4 months preceding the study start, 31.6% of all patients received vaccination for influenza. Table 1 also shows antecedent associations of hospitalization with pneumonia for the total cohort and for the waitlisted subset. On Cox regression, the main associations (arbitrarily defined as an adjusted hazards ratio (AHR) X1.25 or p0.75, Po0.01) of hospitalization with pneumonia were as follows: age 45-64 years and X65 years (AHR 1.26 and 1.48 compared to age o45 years), chronic lung disease (AHR 1.62), duration of renal replacement therapy X10 years (AHR 0.75 compared to o5 years), body mass index (AHR 0.66 for 25.0-29.9 kg/m 2 , 0.58 for X30 kg/m 2 , compared to o18.5 kg/m 2 ), serum albumin (AHR 0.74 for X4.06 vs p3.42), and the occurrence of transplantation during follow-up (AHR 0.68). Other associations with AHR 41.0 included smoking, cardiovascular disease, and history of congestive heart failure. Hemoglobin levels, creatinine levels, and cholesterol levels had associated AHRso1.
In analyses restricted to waitlisted patients, associations of hospitalization with pneumonia (Po0.05) included age 45-64 years and X65 years (AHR 1.50 and 2.38 compared to age o45 years), hypertension, and diabetes as cause of ESRD (AHR 1.53 and 1.87, respectively, compared to glomerulonephritis as cause of ESRD), coronary artery disease (AHR 1.32), congestive heart failure (AHR 1.39), neoplasm (AHR 1.73), and chronic lung disease (AHR 1.63).
Over an average follow-up interval of 3.3 years, 28.9% of the study population was hospitalized with pneumonia. The cumulative probabilities of pneumonia hospitalization were 0.09 at 1 year and 0.36 at 5 years in the overall population, and 0.07 at 1 year and 0.27 at 5 years for waitlisted patients (Po0.0001 vs non-waitlisted) (Figure 1) . Pneumonia was the primary discharge diagnosis in 57.1% of all hospitalizations involving pneumonia. When considering only those hospitalizations with pneumonia as the primary diagnosis, the cumulative probability of pneumonia hospitalization was 0.06 at 1 year and 0.22 at 5 years for all patients, and 0.04 at 1 year and 0.18 at 5 years for patients on the waiting list. Table 2 shows the associated microbiologic spectrum. No organism was specified in 81.8% of cases, 11.1% of cases were attributed to Gram-negative bacteria, and 4.8% were attributed to Gram-positive bacteria.
During the index hospitalization with pneumonia, 384 (12.4%) of the 3101 patients died, 134 with a primary diagnosis of pneumonia and 250 with a secondary diagnosis of pneumonia. For patients with pneumonia, post-pneumonia survival probabilities were 0.55 at 1 year and 0.17 at 5 years (using date of admission of first hospitalization with pneumonia as starting point). The corresponding probabilities in the waitlisted population were 0.73 and 0.44, Po0.0001 vs non-waitlisted (Figure 2) . With Poisson regression analysis, performed in 6-month intervals, adjusted mortality hazards ratios were 4.08 (95% confidence interval (CI) 3.41-4.89) for the 0-to 6-month interval, 3.04 (95% CI 2.58-3.66) for the 6-to 12-month interval, and 2.31 (95% CI 1.97-2.71) for the 12-to 18-month interval (Figure 3 ). Adjusted mortality hazards ratios remained approximately equal to 2.0 for up to 8 years after hospitalization with pneumonia. When this analysis was limited to the 1199 waitlisted patients, adjusted mortality hazards ratios were 4.19 (95% CI 1.47-11.92) for the 0-to 6-month interval, 3.65 (95% CI 1.59-8.40) for the 6-to 12-month interval, and 3.03 (95% CI 1.79-6.61) for 12-to 18-month interval ( Figure 4 ).
DISCUSSION
We found that hospitalization with pneumonia was a relatively common event, one experienced by approximately one-third of dialysis patients by 5 years of follow-up. A microbiologic diagnosis was specified in a minority of cases. As expected, older age and comorbid diseases were associated with a greater risk of pneumonia, and renal transplantation was associated with lower event rates. Finally, hospitalization with pneumonia was associated with lower survival probabilities.
Pneumonia rates were higher than expected from general population estimates. For example, a study of Medicare patients in the US reported a hospitalized communityacquired pneumonia rate of 18.3 per 1000 in 1997. 5 This rate was approximately one-fifth of the rate seen in our study, even though the patients we studied were 17 years younger on average. Tveit et al. 6 reported a pneumonia rate of 2.86 episodes per 100 patient-years in kidney transplant recipients, lower than the rate of hospitalization for pneumonia as the primary diagnosis we observed in chronic dialysis patients waitlisted for transplantation. Pneumonia is a frequent nosocomial infection in hemodialysis patients, occurring at the rate of 1.7 per 1000 patient-days of hospitalization. 3 Hemodialysis patients often have nonrenal comorbid conditions and may be susceptible to infection because the uremic internal milieu leads to impaired chemotaxis, adherence, reactive oxygen species production, and phagocytosis and accelerated apoptosis of granulocytes. 4, 7 Therapeutic immunosuppression is the cornerstone of renal transplantation management; thus, the observation of lower pneumonia rates after renal transplantation suggests that ESRD is a state of profound immunosuppression. ESRD is likely to be a state of inflammatory, endothelial, and redox dysfunction. It is interesting that several characteristics suggestive of the malnutrition-inflammation complex, [8] [9] [10] such as low body mass index, low levels of serum albumin, serum creatinine, and hemoglobin, were associated with greater pneumonia risk in our study. Similar associations have been found among older members of the general population. 11, 12 The 6.3% of our study population receiving renal replacement therapy for X10 years had a lower covariate-adjusted risk of pneumonia. The reason for lower event rates in this group is unclear, but one is tempted to suggest that this long-term survivor cohort may be an intrinsically healthier subgroup.
A specific microorganism was implicated in approximately one of five cases of pneumonia in our study. Similarly, low yields are common in general population studies and in transplant recipients. For example, in a prospective study of four hospitals and one health maintenance organization in the US and Canada, only 29.7% of outpatient cases of pneumonia had a microbiologic test, and only 5.7% had an assigned microbiologic cause; the corresponding figures for inpatients were 95.7 and 29.6%. 13 In kidney transplant recipients hospitalized with a primary diagnosis of pneumonia, 72.5% of all cases lacked a specific microbiologic diagnosis. Sarnak and Jaber 2 reported that pulmonary infectious mortality rates are 14-16 times higher in dialysis patients than in the general population. In our study, the in-hospital mortality rate for hemodialysis patients with a discharge diagnosis of pneumonia was similar to the in-hospital mortality of 11% found in a study of the general US Medicare population 14 and a general population study from Canada. 15 We found that all-cause mortality was higher than expected after an episode of pneumonia, especially in the first year. Throughout the 8 years of follow-up, the risk of death remained approximately twice as high in patients who had an episode of pneumonia, compared with those who did not. The association between hospitalization with pneumonia and long-term mortality has been seen repeatedly in the general population, albeit with considerably better post-event survival estimates. 12, 14, 16 Our study has limitations. It is a retrospective observational study, and pneumonia was identified based on administrative claims; no individual chart review was possible. A single, a priori definition of pneumonia was not applied prospectively in real time. A substantial number of pneumonia cases likely occurred after admission to hospital with another serious illness; in this scenario, an association between pneumonia and mortality could reflect the occurrence of this other serious illness, without a direct causal link between pneumonia and death. Our study involved a Table 1 . In the first interval, death rates in patients who developed pneumonia are compared with death rates in those without pneumonia. In the second interval, death rates of the combined group of patients who survived pneumonia in the first interval and those who developed pneumonia in the second interval are compared with death rates of patients who remained pneumonia free. This process was continued, so that in the nth interval, death rates of patients who developed pneumonia and survived the preceding intervals, as well as those who developed pneumonia in nth interval, are compared with death rates in patients who remained pneumonia free. Table 1 . In the first interval, death rates in patients who developed pneumonia are compared with death rates in those without pneumonia. In the second interval, death rates of the combined group of patients who survived pneumonia in the first interval and those who developed pneumonia in the second interval are compared with death rates of patients who remained pneumonia free. This process was continued, so that in the nth interval, death rates of patients who developed pneumonia and survived the preceding intervals, as well as those who developed pneumonia in nth interval, are compared with death rates in patients who remained pneumonia free.
prevalent cohort of hemodialysis patients; therefore, patients were not studied at a uniform phase of their chronic kidney disease. Pertinent medication data were not readily available, and biochemical data sets were incomplete. In hindsight, it would have been attractive to make accurate assessments of inflammatory, nutritional, and redox status. Unfortunately, no biological samples were stored as part of the study. Finally, the study population was assembled more than 10 years ago, leading to a natural tension between the competing wishes for longer follow-up, higher event rates, and greater statistical power, on the one hand, and generalizability to latter-day hemodialysis populations on the other. Despite its limitations, our study may have practical implications. Both the burden of disease and the associated mortality associations were noteworthy. These findings might encourage the use of preventive measures, timely diagnosis of pneumonia, and prompt initiation of appropriate treatment. For example, a national surveillance study of dialysisassociated diseases in 2000 showed that only 64% of US dialysis patients were vaccinated for influenza and 27% for pneumococcal disease. 17 The current study suggests that the contribution of pneumonia to the morbidity and mortality of dialysis populations may not have received the notice it warrants. Prospective mechanistic, observational, and therapeutic research is greatly needed in this population.
MATERIALS AND METHODS Patients and measurements
For our final sample size of 10 635, we used USRDS standard analysis files (WAITSEQ_KI, WAITSEQ_KP) derived from the United Network for Organ Sharing kidney and kidney/pancreas waitlist file to determine whether patients had been placed on the transplant waiting list before the study start date. Pneumococcal immunization within 5 years and influenza immunization between September 1, 1993 and December 31, 1993 were determined from Part A Medicare in-patient claims and Part B Medicare outpatient claims using Current Procedure Terminology Codes 90655 to 90660, 90724, and G0008 for influenza vaccination, and 90669, 90732, J6065, and G0009 for pneumococcal vaccination. Medicare coverage in the hemodialysis population typically begins in the first year of dialysis therapy or after age 65 years, and most guidelines suggest that high-risk patients should receive pneumococcal vaccination every 5-10 years. Hence, we could not reliably assess appropriateness of pneumococcal vaccination in most patients, and pneumococcal vaccination was not used as an exploratory variable in outcome analyses. 
Outcomes

Analysis
The continuous variables age, duration of renal replacement therapy, body mass index, and K t /V were broken into categories commonly used in other studies. The continuous variables serum levels of albumin, hemoglobin, creatinine, and cholesterol were considered as quintiles. Missing values were treated as separate categories.
Kaplan-Meier analysis was used to measure cumulative eventfree survival times for the following: first pneumonia hospitalization, death in the overall population, and death after hospitalization with pneumonia. Cox regression was used to identify antecedent associations of hospitalization with pneumonia; three types of analyses were performed, one that censored at transplantation, one that did not censor at transplantation, and one that treated transplantation as a time-dependent covariate. Findings were similar with all three methods; only the findings using the last method are presented here. Initial Cox models evaluating the association between pneumonia and mortality showed substantial violation of the assumption of constant hazards ratios over time; instead, we used interval Poisson analysis, both censored and uncensored at transplantation, to evaluate the association between hospitalization with pneumonia and mortality. Because the findings were similar, only the findings from the uncensored model are presented here. All outcome analyses were repeated in the subset of patients waitlisted for transplantation before the study start date, and were performed using SAS for Windows, version 8.2 (SAS Institute, Cary, NC, USA).
